NOverview
New York Cancer & Blood Specialists delivers cancer and blood disorder care using advanced medical technology and personalized treatment plans. Their services combine standard oncology care with participation in cutting-edge clinical trials, all provided within New York communities to keep care close to patients’ families. Treatments are tailored to each patient’s needs, and care is designed to be affordable, with a focus on patient-centered experiences. The company differentiates itself by prioritizing accessible, neighborhood-based care and integrating clinical research into routine treatment. The goal is to improve patient outcomes and contribute to the search for cures through innovative therapies and trials.
Work here?Claim your company
About New York Cancer & Blood Specialists
Industries
Company Size
501-1,000
Company Stage
N/A
Total Funding
N/A
Headquarters
Town of Brookhaven, United States
Founded
N/A
Get referred to New York Cancer & Blood Specialists
See people who can refer or advise you
Simplify's take
What believers are saying
- NYCBS added Drs. Lachhar, Zweifler, and Levenson across August-September 2026, expanding specialist depth.
- Riverhead’s November 11, 2026 page shows on-site oncology, hematology, infusion, radiation, and imaging.
- Its July 2026 Lake Success opening replaced an older site, signaling continued capital deployment.
What critics are saying
- Recruiting physicians across New York costs heavily; September 2026 hiring proves ongoing dependence on talent.
- NYCBS relies on New York reimbursement and local referrals; payer pressure hits margins immediately.
- If referral volume softens, its fixed-site network turns into stranded overhead within months.
What makes New York Cancer & Blood Specialists unique
- NYCBS spans 30-plus New York sites, including Riverhead, Lake Success, and Washington Heights in 2026.
- Its July 2026 Lake Success center combines infusion, imaging, and multidisciplinary oncology services.
- Central Park and Riverhead locations advertise access to cutting-edge clinical trials in 2026.
Help us improve and share your feedback! Did you find this helpful?
Benefits
- Health Insurance
- Dental Insurance
- Vision Insurance
- Life Insurance
- Disability Insurance
- 401(k) Plan
- Paid Time Off
- Paid Holidays
Company News
N-Power Medicine and New York Cancer & Blood Specialists have partnered to scale Prospective External Control Arms (ProECA) in community oncology. The collaboration combines N-Power's ProECA platform with NYCBS's research programme to accelerate oncology drug development. N-Power's ProECA platform creates standalone, protocol-driven control arms by collecting trial-grade data on patients receiving standard-of-care therapy. This approach can reduce the need for randomisation in clinical trials and accelerate the development of new cancer therapies. NYCBS will join the N-Power Network and offer ProECA programmes to its patients, starting with non-small cell lung cancer. The practice brings over 90 medical oncologists at more than 30 locations across New York. The N-Power Network now spans over 50 community oncology sites across multiple large health systems.
N-Power Medicine and New York Cancer & Blood Specialists partner to scale Prospective External Control Arms (ProECA) in community oncology. * 1 hr ago N-Power Medicine, a company transforming oncology drug development, and New York Cancer & Blood Specialists (NYCBS), one of the nation's largest independent community oncology practices and a longtime leader in clinical research, today announced a strategic partnership to accelerate the generation of N-Power's Prospective External Control Arms (ProECAs). This novel approach is designed to reduce the size of oncology clinical trials and bring new therapies to patients years sooner. As part of the partnership, NYCBS will participate in the N-Power Network and offer ProECA programs to its patients, beginning in non-small cell lung cancer (NSCLC). N-Power's ProECA platform builds standalone, protocol-driven control arms by collecting trial-grade data on patients receiving standard-of-care therapy. Unlike retrospective approaches that rely on data generated without a standardized framework, ProECAs are designed from the outset with protocolized data collection and imaging-based endpoints aligned with clinical trial standards. ProECAs can reduce the need for randomization, improve decision-making in early development and advance promising molecules into late-phase trials. NYCBS brings more than 90 medical oncologists at over 30 locations across New York, adding a large, diverse patient population to the N-Power Network and providing its patients with broader access to clinical research as part of the care they already receive. The N-Power Network spans more than 50 community oncology sites across multiple large health systems. Pharmaceutical and biotech partners already use N-Power's NSCLC ProECA to accelerate early development and Phase 4 programs, and N-Power plans to expand across major cancer indications, with a colorectal program launching later this year. "Clinical research has long been central to how we care for patients at NYCBS, and this partnership extends that commitment across our entire practice," said Justas Lauzadis, PhD, chief research officer of New York Cancer & Blood Specialists. "By building trial-grade data collection into everyday care, we give more patients the opportunity to contribute to research without adding burden for them or our physicians. Adopting prospective external control arms enhances our research program for our patients living with NSCLC, and we look forward to expanding ProECA to additional indications." "We are thrilled to welcome New York Cancer & Blood Specialists to the N-Power Network," said Mark Lee, MD, PhD, co-founder and chief executive officer of N-Power Medicine. "NYCBS is one of the most respected independent oncology practices in the country, and its scale, research experience and deep roots in New York communities make it an ideal partner for ProECA. Together, we can generate the high-quality evidence needed for faster, smarter drug development while bringing more research opportunities to thousands of patients close to home." About N-Power Medicine N-Power Medicine has built a national network of community oncology centers, creating the first "always-on" Prospective External Control Arm (ProECA) platform that enables drug developers to reduce or replace randomized control arms and run faster, smaller, more efficient clinical trials, while simultaneously expanding access to clinical research and innovation for physicians and patients in the communities where they live. About New York Cancer & Blood Specialists New York Cancer & Blood Specialists is a leading oncology practice dedicated to providing world-class, patient-centered, and affordable care to individuals with cancer and blood disorders throughout New York State. With locations across Long Island, New York City, and the Hudson Valley, its mission is to bring world-class cancer care close to home, where patients can heal with the support of family and community. Media gallery
New York Cancer & Blood Specialists welcomes Medical oncologist-hematologist Dr. Jacob Levenson. Bronx, NY, September 01, 2026 -( PR.com )- New York Cancer & Blood Specialists (NYCBS), one of the Nation's leading oncology practices, proudly announces the addition of hematologist-oncologist, Dr. Jacob Levenson. Beginning August 31, 2026, Dr. Levenson will be practicing at NYCBS's office located at 2330 Eastchester Road, Bronx, NY 10469. "We are pleased to welcome Dr. Levenson to New York Cancer & Blood Specialists," said Dr. Jeff Vacirca, CEO of NYCBS. "His clinical experience, strong research background, and focus on advancing precision therapies in oncology make him a valuable addition to our team. We look forward to the expertise he will bring to our patients and our continued efforts to advance high-quality cancer care." Dr. Levenson's clinical experience spans both inpatient and outpatient oncology settings. He has managed complex solid tumors and hematologic malignancies and provides on-site oversight for chemotherapy and immunotherapy infusions, including the recognition and management of infusion reactions and urgent oncologic complications. Dr. Levenson earned his Doctor of Medicine from the University of Central Florida College of Medicine after completing a Bachelor in Science in Biology with a minor in Economics at Brandeis University. He completed his Internal Medicine Residency at the Zucker School of Medicine at Hofstra/Northwell, North Shore University Hospital, and Long Island Jewish Medical Center, where he completed his Hematology Oncology Fellowship. "I am excited to join New York Cancer & Blood Specialists and contribute to a practice committed to advancing cancer care," said Dr. Levenson. "I look forward to applying my clinical and research experience to help improve treatment strategies and outcomes for patients while continuing to explore advances in precision oncology." Dr. Levenson's research focuses on liver-directed and precision therapies in gastrointestinal malignancies. His work includes research on hepatic artery infusion pump therapy for unresectable colorectal liver metastases, circulating tumor DNA during total neoadjuvant therapy for rectal cancer, and data analytics in pancreatic cancer. He is a co-first author of an American Society of Clinical Oncology Education Book chapter on liver-directed therapies in colorectal cancer and is a member of the American Society of Hematology and the American Society of Clinical Oncology. To make an appointment with Dr. Levenson, please call (718) 732-4000. For more information, please visit nycancer.com. About NYCBS New York Cancer & Blood Specialists is a leading oncology practice dedicated to providing world-class, patient-centered, and affordable care to individuals with cancer and blood disorders throughout New York State. With locations across Long Island, New York City, and the Hudson Valley, its mission is to bring world-class cancer care close to home, where patients can heal with the support of family and community. New York Cancer & Blood Specialists Mike Scanlon, Marketing Project Manager 631-574-8366
New York Cancer & Blood Specialists welcomes hematologist-oncologist Dr. Michael Brodsky. New York, NY, August 11, 2026 -( PR.com )- New York Cancer & Blood Specialists (NYCBS), one of the Nation's leading oncology practices, proudly announces the addition of Dr. Michael Brodsky. Beginning August 3, 2026, Dr. Brodsky will be practicing at NYCBS's office located at 157 E 32nd Street, New York, NY 10016. "We look forward to welcoming Dr. Brodsky to our practice," said Dr. Jeff Vacirca, CEO of NYCBS. "His outstanding clinical training, and commitment to delivering compassionate, evidence-based care make him an exceptional addition to our team. Dr. Brodsky's expertise strengthens our mission of providing high-quality cancer care to patients throughout New York." Dr. Brodsky has extensive experience caring for medically complex and socioeconomically diverse patient populations and is focused on leveraging the latest advances in oncology to improve patient care, particularly in managing complications related to breast cancer treatment. He completed both his Internal Medicine Residency and Hematology and Medical Oncology Fellowship at Montefiore Medical Center, Albert Einstein College of Medicine. Dr. Brodsky earned a Bachelor of Arts in History and International Studies from Northwestern University and completed a post-baccalaureate premedical program at Mount Holyoke College before receiving his Doctor of Medicine from SUNY Downstate College of Medicine. "I am excited to join New York Cancer & Blood Specialists and collaborate with a team committed to advancing cancer care through both clinical excellence and research," said Dr. Brodsky. "I look forward to helping patients receive the highest quality treatment while continuing to explore new approaches that improve outcomes and quality of life." Throughout his training, Dr. Brodsky participated in clinical research focused on breast cancer, chemotherapy-induced peripheral neuropathy, pancreatic cancer, and hematologic disorders. His work includes helping launch a phase II clinical trial investigating a novel agent to prevent taxane-induced peripheral neuropathy in patients with breast cancer, as well as authoring and co-authoring multiple research publications and presentations. He remains committed to advancing breast cancer research while providing high-quality, patient-centered care to patients with cancer and blood disorders. To make an appointment with Dr. Brodsky, please call (212) 689-6791. For more information, please visit nycancer.com. About NYCBS New York Cancer & Blood Specialists is a leading oncology practice dedicated to providing world-class, patient-centered, and affordable care to individuals with cancer and blood disorders throughout New York State. With locations across Long Island, New York City, and the Hudson Valley, its mission is to bring world-class cancer care close to home, where patients can heal with the support of family and community. New York Cancer & Blood Specialists Mike Scanlon, Marketing Director 631-574-8366
New York Cancer & Blood Specialists welcomes oncologist-hematologist Dr. Brendon Fusco. Brooklyn, NY, August 11, 2026 -( PR.com )- New York Cancer & Blood Specialists (NYCBS), one of the Nation's leading oncology practices, proudly announces the addition of Dr. Brendon Fusco, a board-certified hematologist-oncologist dedicated to providing compassionate, evidence-based care for patients with cancer and blood disorders. Beginning August 3, 2026, Dr. Fusco will be practicing at NYCBS's office located at 2236 Nostrand Avenue, Brooklyn, NY 11210. "We look forward to welcoming Dr. Fusco to our practice," said Dr. Jeff Vacirca, CEO of NYCBS. "His exceptional clinical training, dedication to compassionate patient care, and commitment to advancing oncology through research make him an outstanding addition to our team. Dr. Fusco's expertise further strengthens our mission of delivering high-quality cancer care to patients throughout New York." Dr. Fusco is committed to delivering individualized treatment while supporting patients and their families throughout every stage of care. He completed his Internal Medicine Residency at Robert Wood Johnson School of Medicine before completing a Hematology and Medical Oncology Fellowship at Montefiore Medical Center and Albert Einstein College of Medicine. During his training, he was recognized for excellence in compassionate patient care, professionalism, and teaching through multiple institutional and national awards. Dr. Fusco earned his Doctor of Medicine from the Virginia Tech Carilion School of Medicine after completing a Bachelor of Science in Neuroscience, magna cum laude, from the Ohio State University Honors College. He also completed a Graduate Certificate in Translational Medicine at the Virginia Tech Carilion School of Medicine. "I am honored to join New York Cancer & Blood Specialists and practice as part of a team committed to providing exceptional cancer care," said Dr. Fusco. "I look forward to partnering with my patients and their families to deliver personalized, evidence-based treatment while supporting them throughout every stage of their care." Throughout his training, Dr. Fusco contributed extensively to clinical and translational research in hematologic malignancies, thoracic oncology, stem cell transplantation, and health disparities. His work has resulted in several peer-reviewed publications, national presentations, and recognition including the ASCO Gastrointestinal Cancers Symposium Merit Award. He is a member of the American Society of Clinical Oncology, the American Society of Hematology, the American Medical Association, and the Arnold P. Gold Humanism in Medicine Honor Society. To make an appointment with Dr. Fusco, please call (718) 406-9454. For more information, please visit nycancer.com. About NYCBS New York Cancer & Blood Specialists is a leading oncology practice dedicated to providing world-class, patient-centered, and affordable care to individuals with cancer and blood disorders throughout New York State. With locations across Long Island, New York City, and the Hudson Valley, its mission is to bring world-class cancer care close to home, where patients can heal with the support of family and community. New York Cancer & Blood Specialists Mike Scanlon, Marketing Director 631-574-8366
New York Cancer & Blood Specialists is Hiring for 59 Jobs on Simplify!
Find jobs on Simplify and start your career today
Don't see your dream role? Check out thousands of other roles on Simplify.Browse all jobs
About New York Cancer & Blood Specialists
Industries
Company Size
501-1,000
Company Stage
N/A
Total Funding
N/A
Headquarters
Town of Brookhaven, United States
Founded
N/A
New York Cancer & Blood Specialists is Hiring for 59 Jobs on Simplify!
Find jobs on Simplify and start your career today
Don't see your dream role? Check out thousands of other roles on Simplify.Browse all jobs